Loh C S, MacRobert A J, Bedwell J, Regula J, Krasner N, Bown S G
National Medical Laser Centre, Faculty of Clinical Sciences, University College London, Rayne Institute, UK.
Br J Cancer. 1993 Jul;68(1):41-51. doi: 10.1038/bjc.1993.284.
Endogenously synthesised protoporphyrin IX (PpIX) following the administration of 5-amino-laevulinic acid (ALA) is an effective photosensitiser for photodynamic therapy (PDT). Following intravenous administration, PpIX accumulates predominantly in mucosa of hollow viscera and on light exposure, mucosal ablation results with relative sparing of the submucosa and muscularis layers. Oral administration is effective with ALA in contrast to conventional exogenous photosensitisers such as haematoporphyrin derivative and phthalocyanines. Oral administration of ALA is also simpler, safer, cheaper and more acceptable to patients. We studied the porphyrin sensitisation kinetics profile in the stomach, colon and bladder in normal rats following enterally and parenterally administered ALA using microscopic fluorescence photometric studies of frozen tissue sections. Mucosal cells in all three organs exhibit higher fluorescence levels as compared with underlying smooth muscle following both intravenous and oral administration. Peak concentration were seen 4 h after sensitisation at the highest doses used (200 mg kg-1 i.v., 400 mg kg-1 oral), and slightly earlier with lower doses. The temporal kinetics of both routes of administration were similar although a higher oral dose was required to achieve the same tissue concentration of PpIX. The highest level of fluorescence was achieved in the gastric mucosa and in decreasing levels, colonic and bladder mucosa. A similar degree of mucosal selectivity was achieved in each organ with each route of administration but an oral dose in excess of 40 mg kg-1 was required to achieve measurable PpIX sensitisation. In a pilot clinical study, two patients with inoperable rectal adenocarcinomas were given 30 mg kg-1 and one patient with sigmoid colon carcinoma was given 60 mg kg-1 ALA orally. Serial biopsies of normal and tumour areas were taken over the subsequent 24 h. Fluorescence microscopy of these specimens showed maximum accumulation of PpIX 4 to 6 h after administration of 30 mg kg-1 ALA. There was greater PpIX accumulation in tumour than adjacent normal mucosa in two patients. Preferential PpIX accumulation in tumour was greater in the patient receiving 60 mg kg-1 ALA.
给予5-氨基-γ-酮戊酸(ALA)后内源性合成的原卟啉IX(PpIX)是光动力疗法(PDT)的一种有效光敏剂。静脉给药后,PpIX主要积聚在中空脏器的黏膜中,光照后,黏膜发生消融,而黏膜下层和肌层相对保留。与传统的外源性光敏剂如血卟啉衍生物和酞菁相比,ALA口服给药有效。ALA口服给药也更简单、更安全、更便宜且更易为患者接受。我们使用冷冻组织切片的显微荧光光度研究,对正常大鼠经肠内和肠外给予ALA后胃、结肠和膀胱中的卟啉敏化动力学特征进行了研究。静脉和口服给药后,所有三个器官中的黏膜细胞与下方的平滑肌相比均表现出更高的荧光水平。在所用最高剂量(静脉注射200 mg/kg,口服400 mg/kg)致敏后4小时出现峰值浓度,较低剂量时峰值出现稍早。尽管达到相同的PpIX组织浓度需要更高的口服剂量,但两种给药途径的时间动力学相似。胃黏膜中的荧光水平最高,其次是结肠和膀胱黏膜,荧光水平逐渐降低。每种给药途径在每个器官中都实现了相似程度的黏膜选择性,但需要超过40 mg/kg的口服剂量才能实现可测量的PpIX敏化。在一项初步临床研究中,两名无法手术的直肠腺癌患者口服30 mg/kg的ALA,一名乙状结肠癌患者口服60 mg/kg的ALA。在随后的24小时内对正常和肿瘤区域进行系列活检。这些标本的荧光显微镜检查显示,给予30 mg/kg的ALA后4至6小时PpIX积聚最多。两名患者肿瘤中的PpIX积聚均多于相邻的正常黏膜。接受60 mg/kg的ALA的患者肿瘤中PpIX的优先积聚更多。